Mineralys Therapeutics Inc. (MLYS)
NASDAQ: MLYSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
MLYS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.95B
- EPS (TTM)
- -$4.25
- Dividend yield
- None
- 52-week range
- 21.50 – 47.65
- Day range
- 21.50 – 22.44
- Volume / Avg
- 989.01K / 1.03M
- Beta
- —
- Shares outstanding
- 88.41M
52-week range
MLYS stock today
Shares of Mineralys Therapeutics (MLYS) finished higher on Oct 7 at $22.09, a gain of 0.64% or $0.14 per share, versus the S&P 500's 0.22% decline. Shares are 53.6% below their 52-week high of $47.65, set on Nov 12, 2025 and 2.7% above the 52-week low of $21.50, near the bottom of the past year's range. MLYS is down 39.1% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 41.3%.
Mineralys Therapeutics has posted a net loss over the last twelve months (EPS of -$4.25), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Mineralys Therapeutics
Company profileMineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Jon Congleton
- Headquarters
- Radnor, PA
- Employees
- 76
- IPO year
- 2023
- Website
- mineralystx.com
Analyst forecast
ForecastConsensus (10 analysts)
none
Avg. price target
$48.50+119.56%
- Strong buy 0
- Buy 9
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
MLYS news
All MLYS newsMineralys Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LKFTLakefront Biotherapeutics ADR | 30.00 | +2.32% | $1.96B | vs MLYS |
| ZYMEZymeworks Inc. | 26.53 | +3.43% | $1.90B | vs MLYS |
| GPCRStructure Therapeutics Inc. ADR | 26.68 | -2.88% | $1.90B | vs MLYS |
| AGIOAgios Pharmaceuticals Inc. | 31.79 | +0.22% | $1.90B | vs MLYS |
| PVLAPalvella Therapeutics Inc. | 130.59 | +2.02% | $1.88B | vs MLYS |
| PRGOPerrigo Company plc | 14.55 | +3.93% | $2.01B | vs MLYS |
| SRPTSarepta Therapeutics Inc. | 17.50 | +1.10% | $1.85B | vs MLYS |
| XERSXeris Biopharma Holdings Inc. | 10.11 | +0.40% | $1.84B | vs MLYS |
Indexes, lists and sector
Mineralys Therapeutics stock FAQ
What is Mineralys Therapeutics's stock price today?
MLYS last traded at $22.09 as of Oct 7, 4:00 PM EDT, up 0.64% on the day. Prices are delayed at least 15 minutes.
Who is Mineralys Therapeutics's CEO?
Dr. Jon Congleton is the chief executive officer of Mineralys Therapeutics Inc., which has about 76 employees.
What is the MLYS 52-week high?
The 52-week high for MLYS is $47.65 and the 52-week low is $21.50. The stock is currently 53.6% below its high.